STOCK TITAN

Sensei Biotherapeutics, Inc. - SNSE STOCK NEWS

Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.

Sensei Biotherapeutics, Inc. (SNSE) is a clinical-stage biotechnology pioneer developing tumor microenvironment-activated immunotherapies. This page aggregates all material news and regulatory disclosures about the company's innovative TMAb™ platform and clinical programs.

Investors and industry observers will find timely updates on clinical trial progress, partnership announcements, financial disclosures, and scientific developments. Our curated collection ensures efficient tracking of key milestones in Sensei's quest to create conditionally active cancer therapies.

The repository includes earnings reports, FDA communications, research collaborations, and peer-reviewed publication highlights. All content is vetted for relevance to SNSE's core focus on overcoming immune suppression in solid tumors through pH-sensitive antibody engineering.

Bookmark this page for structured access to Sensei's evolving pipeline updates and corporate announcements. Regularly refreshed content supports informed decision-making about this innovative player in next-generation immuno-oncology.

Rhea-AI Summary

Sensei Biotherapeutics (Nasdaq: SNSE) reported Q2 2024 financial results and business highlights. The company presented promising Phase 1/2 clinical data for SNS-101 at ASCO 2024, demonstrating early signs of clinical activity in immunotherapy-resistant patients. Patient enrollment is advancing in the dose expansion portion of the Phase 1/2 study, with initial data expected in Q4 2024. Sensei's cash position stands at $52.3 million, providing runway into Q4 2025. Financial results show R&D expenses of $4.6 million and G&A expenses of $3.2 million for Q2 2024. The company reported a net loss of $7.1 million, an improvement from $9.4 million in Q2 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.56%
Tags
-
Rhea-AI Summary

Sensei Biotherapeutics, a clinical stage immuno-oncology company, announced its participation in the Jefferies Global Healthcare Conference. The event will take place in New York on June 6, 2024, at 8:30 a.m. ET. John Celebi, President and CEO, is set to present. The presentation will be webcast live on the investors section of Sensei's website, with a replay available for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.07%
Tags
conferences
-
Rhea-AI Summary

Sensei Biotherapeutics has released promising data from the Phase 1 dose escalation study of their human monoclonal antibody, SNS-101, targeting the immune checkpoint VISTA. The study shows that SNS-101 is well-tolerated with no dose-limiting toxicities and demonstrates signs of clinical activity, particularly in tumor types typically unresponsive to PD-1 therapies.

Among the 34 patients, promising results were observed in those with microsatellite stable (MSS) endometrial cancer, MSS colorectal cancer, pembrolizumab-resistant renal cell carcinoma, and HPV-positive head and neck cancer.

The pharmacokinetic profile of SNS-101 supports once every three-week dosing, showing linear elimination kinetics and dose-proportional increases in exposure. The ongoing dose expansion portion aims to enroll more patients, with initial data anticipated by the end of 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.52%
Tags
Rhea-AI Summary

EGLE Therapeutics announced the appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and John Celebi, as Independent Board Member. Dr. Motlagh's expertise will drive clinical strategy and development, focusing on advancing the company's pipeline in oncology and auto-immunity. Mr. Celebi brings over 25 years of experience in building biotechnology companies. His extensive background includes serving as President and CEO of Sensei Biotherapeutics (NASDAQ: SNSE) and holding leadership positions in various biotech firms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
management
-
Rhea-AI Summary

Sensei Biotherapeutics, Inc. reported financial results for Q1 2024 and recent business highlights, including clinical trial progress, upcoming data presentations, and a strong balance sheet with cash runway into Q4 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.67%
Tags
-
Rhea-AI Summary
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) will present topline clinical data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting. The data includes results from the Phase 1/2 trial of SNS-101, a human monoclonal antibody targeting the immune checkpoint VISTA. The presentation will cover monotherapy and combination dose escalation portions of the trial, focusing on patients with advanced solid tumors. The poster presentation will take place on June 1, 2024, in Chicago, IL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
conferences clinical trial
Rhea-AI Summary
Sensei Biotherapeutics, Inc. (SNSE) will participate in Canaccord Genuity's Horizons in Oncology Virtual Conference to discuss KRAS and VISTA targeting in cancer therapy. Dr. Shiraj Sen will represent the company and share insights on the Phase 1/2 clinical trial for SNS-101.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.28%
Tags
conferences
-
Rhea-AI Summary
Sensei Biotherapeutics, Inc. (SNSE) announces the publication of a research paper in Nature Communications detailing the development of SNS-101, a pH-sensitive monoclonal antibody targeting VISTA to suppress T-cell activation in cancer patients. The paper highlights the unique mechanism of SNS-101 in mitigating CRS risk and maintaining a favorable safety profile, potentially revolutionizing VISTA-directed immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
none
-
Rhea-AI Summary
Sensei Biotherapeutics, Inc. (SNSE) will participate in the 3rd Annual VISTA Symposium to discuss Anti-VISTA Immunotherapies in Clinical Development. The symposium will focus on the role of VISTA in cancer immunotherapy and ongoing clinical development of anti-VISTA therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.43%
Tags
conferences
Rhea-AI Summary
Sensei Biotherapeutics, Inc. (SNSE) announces the presentation of preclinical data on its immuno-oncology programs at scientific conferences. The company will showcase its innovative therapies targeting immune checkpoint pathways to enhance cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.56%
Tags
conferences clinical trial
Sensei Biotherapeutics, Inc.

Nasdaq:SNSE

SNSE Rankings

SNSE Stock Data

10.22M
16.60M
34.22%
9.37%
0.58%
Biotechnology
Pharmaceutical Preparations
Link
United States
ROCKVILLE